Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNT-101 SAD/MAD and Food-Effect Study in Healthy Adults
NCT07169318Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VNT-101 in influenza (18 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Grade change from baseline in any 12-lead ECG reading, Grade change from baseline in any clinical laboratory parameter and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
VNT-101
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07169318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169318.